key: cord-0762375-rwtfj0ts
authors: Dong, Zi-yuan; Xiang, Bing-Jie; Jiang, Min; Sun, Ming-jun; Dai, Cong
title: The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis
date: 2020-10-27
journal: J Clin Gastroenterol
DOI: 10.1097/mcg.0000000000001424
sha: cb38a29f2ee525a7a73ff62b09bd29bc6064d889
doc_id: 762375
cord_uid: rwtfj0ts

BACKGROUND: The worldwide outbreak of COVID-19 infected millions of people. Some patients had gastrointestinal (GI) symptoms, abnormal liver function, digestive system disease and liver disease. AIM: To investigate the prevalence of GI symptoms, abnormal liver function, digestive system disease and liver disease in patients with COVID-19 by a systematic review and meta-analysis. METHODS: We searched PubMed, Ovid Embase, Medline, and 2 Chinese databases. Primary outcomes were the prevalence of GI symptoms, abnormal liver function, digestive system disease, and liver disease. Different studies were included in different subset analysis. These outcomes were estimated with proportions, odds ratio, 95% confidence interval (CI) and P-value by Stata SE 15.1. RESULTS: Thirty-one studies involving 4682 patients were included. The most significant GI symptoms were diarrhea (0.08, 95% CI: 0.06-0.11) and anorexia (0.17, 95% CI: 0.06-0.27). The most significant abnormal liver function was increased alanine aminotransferase (ALT) (0.25, 95% CI: 0.16-0.33). A total of 5% of the patients had digestive system disease (95% CI: 0.02-0.08). A total of 3% of the patients had liver disease (95% CI: 0.02-0.05). The prevalence of nausea and vomiting, diarrhea, abnormal liver function, digestive system disease, and liver disease was higher in Wuhan group. The prevalence of diarrhea was higher in non-China group. Patients in severe/intensive care unit group were more likely to have diarrhea, anorexia, abdominal pain increased aspartate aminotransferase, and increased ALT. CONCLUSION: The most significant GI symptoms were anorexia and diarrhea. The most significant abnormal liver function was increased ALT. Severe patients were more likely to have GI symptoms and abnormal liver function.

I n December 2019, several cases of pneumonia with unknown reason emerged in Wuhan, Hubei province, China. 1,2 Chinese Center for Disease Control and Prevention (China CDC) identified a novel coronavirus, which was named 2019 novel coronavirus (2019-nCoV). 3 2019 novel coronavirus disease (COVID-19) spread through China rapidly in last 3 months, thus far, there were > 80 thousand confirmed cases and > 3 thousand dead cases in China. At present, the epidemic has been contained successfully in China with effective measures. However, COVID-19 is affecting many countries and territories outside China, as of April 3, 2020, > 1 million cases of COVID-19 have been reported, among which > 50 thousand patients have died. 4 On March 11, 2020, World Health Organization (WHO) pronounced that COVID-19 could be characterized as pandemic. 5 The severity of COVID-19 can vary from mild to severe, some patients have only influenza-like symptoms of fever, cough, myalgia, and fatigue, however, a few patients can progress rapidly to acute respiratory distress syndrome, acute respiratory failure, and other serious complications. Previous studies have shown that 5% of the patients were admitted to the intensive care unit (ICU), 2.3% of the patients need invasive mechanical ventilation and 1.4% of the patients died. [6] [7] [8] Except for typical respiratory symptoms, gastrointestinal (GI) symptoms such as diarrhea, nausea, and vomiting are worthy of attention. A multicenter research in China shown that 3.8% of the patients had diarrhea, 5% of the patients had nausea or vomiting. 8 In the study of Wang et al, 9 10 .1% of the patients had nausea and diarrhea at the onset of illness followed by fever and dyspnea. Besides, abnormal liver function was observed in a substantial portion of the patients. In the study of Chen et al, 7 43% of the patients had differing degrees of liver insufficiency with increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT), 18% of the patients had increased total bilirubin (TBil). Another study found that liver damage was more likely to be observed in severe patients during the process of disease. 10 Previous studies have shown that COVID-19 was more likely to affect populations with comorbidities. In the study of Chen and colleagues, 11% of the patients got COVID-19 with underlying digestive system disease. With the rapid spread of COVID-19, the better understanding of clinical features will facilitate efforts to control COVID-19. The aim of this meta-analysis is to identify the

We included studies which met criteria as follows: (1) studies aimed at COVID-19; (2) studies provided information about GI symptoms, abnormal liver function, digestive system disease, and liver disease; (3) studies designed by randomized controlled trials (RCTs), prospective cohorts, retrospective cohorts, and open-label; (4) full text. The exclusion criteria were as follows: (1) studies published as reviews, letters, case reports, editorials, comments, conference abstracts, and family-based studies; (2) studies only describe these situations such as GI symptoms, abnormal liver function, digestive system disease, liver disease, and lacks specific data.

Information was extracted from each study, including baseline characteristics such as age, sex, region, severity of disease, clinical outcome, date of cases collection, GI symptoms such as nausea, vomiting, diarrhea, abdominal pain, anorexia, belching and constipation, abnormal liver function such as increased AST, ALT, and TBil, digestive system disease, and liver disease. We defined studies performed in Wuhan as Wuhan group, studies performed outside Wuhan in China as non-Wuhan group, studies performed in China as China group and studies performed outside China as non-China group. We defined the patients who had severe symptoms or received ICU care as severe/ICU group, the patients who had general symptoms or did not receive ICU care as general/non-ICU group. Primary outcome was the prevalence of GI symptoms. Secondary outcomes were the prevalence of abnormal liver function, digestive system disease, and liver disease.

The data was analyzed by Stata SE 15.1, the proportion and 95% confidence interval (CI) was used to calculate the prevalence. Forest plots were used to present data visually. Heterogeneity was evaluated using the Cochran's Q test and I 2 statistics, P-value < 0.10 or I 2 > 50% means the heterogeneity was significant. The random-effects model was used if heterogeneity was significant, otherwise, the fixed-effects model was adopted. Publication bias was assessed with funnel plots and Egger's test. Subgroup analysis were performed based on region. Odds ratio (OR), 95% CI, and P-value were computed to compare the difference based on severity of disease. P-value <0.05 means the difference between groups was statistically significant. Different studies were included in different subset analysis.

We initially retrieved 3154 unique citations from PubMed, Ovid Embase, Medline, and 2 Chinese databases (CNKI and Wanfang Data). A total of 569 studies were excluded in the first screening because of duplication. After reading the titles, abstracts, and full-text of citations, 2554 literatures were excluded and 31 studies with a total of 4682 patients were included (Fig. 1) . In this meta-analysis, the time span of cases collection was from December 11, 2019 to February 28, 2020. The median age of patients ranged from 36 to 62 years, 55% of the patients were male ( Table 1) .

In total, 26 studies were included to analyze the prevalence of nausea, vomiting, diarrhea, abdominal pain, and anorexia which we focused on in this meta-analysis. In addition, the study of Zhang et al 31 reported 7 patients with belching. The study of Wang et al 24 reported a patient with constipation. The prevalence of nausea and vomiting was 7% (95% CI: 0.04-0.09), heterogeneity was significant (P < 0.0001, I 2 = 85.8%), the funnel plot and Egger's test revealed evidence of publication bias (t = 2.57, 95% CI: 0.46-4.55, P = 0.019). The prevalence of diarrhea was 8% (95% CI: 0.06-0.11), heterogeneity was significant (P < 0.0001, I 2 = 86.4%) (Fig. 2) , the funnel plot and Egger's test revealed the evidence of publication bias (t = 3.02, 95% CI: 0.77-4.13, P = 0.006). The prevalence of abdominal pain was 3% (95% CI: 0.01-0.05), heterogeneity was significant (P = 0.005, I 2 = 73.4%), the funnel plot and Egger's test revealed no evidence of publication bias (t = 2.86, 95% CI: −0.46 to 8.77, P = 0.064). The prevalence of anorexia was 17% (95% CI: 0.06-0.27), heterogeneity was significant (P < 0.0001, I 2 = 95.6%) ( Fig. S1 in Supplementary Appendix, Supplemental Digital Content 1, http://links.lww.com/JCG/A622), the funnel plot and Egger's test revealed no evidence of publication bias (t = 2.10, 95% CI: −1.31 to 13.34, P = 0.089). We utilized random-effect model to analyze the prevalence of GI symptoms.

Fourteen studies were included to analyze the prevalence of increased AST, ALT, and TBil. The upper limit of normal value of AST, ALT, and TBil was 40 U/L, 40 to 64 U/L, and 17.1 to 26 μmol/L, respectively. In total, 24% of the patients had increased AST (95% CI: 0.16-0.32), heterogeneity was significant (P < 0.0001, I 2 = 94.7%) ( Fig. S2 in Supplementary Appendix, Supplemental Digital Content 2, http://links.lww. com/JCG/A623), the funnel plot and Egger's test revealed no evidence of publication bias (t = 1.49, 95% CI: −1.61 to 8.30, P = 0.165). A total of 25% of the patients had increased ALT (95% CI: 0.16-0.33), heterogeneity was significant (P < 0.0001, I 2 = 92.9%) (Fig. 3) , the funnel plot and Egger's test revealed no evidence of publication bias (t = 0.99, 95% CI: −3.21 to 7.80, P = 0.356). A toal of 13% of the patients had increased TBil (95% CI: 0.05-0.20), heterogeneity was significant (P < 0.0001, I 2 = 92.5%), the funnel plot and Egger's test revealed evidence of publication bias (t = 1.12, 95% CI: −11.69 to 19.89, P = 0.38). All the results were analyzed by random-effect model.

Seventeen studies were included to analyze the prevalence of digestive system disease and liver disease. The disease categories were not mentioned in most studies. The study of Easom et al 16 In this meta-analysis, 5% of the patients had digestive system disease (95% CI: 0.02-0.08), heterogeneity was significant (P < 0.0001, I 2 = 76.5%) (Fig. 4) , the funnel plot and Egger's test revealed evidence of publication bias (t = 5.61, 95% CI: 1.68-4.53, P = 0.002). In total, 3% of the patients had liver disease (95% CI: 0.02-0.05), heterogeneity was significant (P = 0.023, I 2 = 50.6%) (Fig. 5) , the funnel plot and Egger's test revealed no evidence of publication bias (t = 2.18, 95% CI: −0.03 to 2.83, P = 0.054). Both the results were analyzed by fixed-effects model.

Fourteen studies were performed in Wuhan, 14 studies were performed outside Wuhan in China. Only 1 study was performed in United Kingdom. Two studies including patients in and outside Wuhan in China, however, the difference of clinical characteristics between patients in and outside Wuhan in China were not mentioned. Ultimately, 28 studies were included to analyze the difference between Wuhan group and non-Wuhan group. And 31 studies were included to analyze the difference between China group and non-China group.

In Wuhan group, 58% of the patients were male. The prevalence of nausea and vomiting was 8% (95% CI: 0.04-0.12), the prevalence of diarrhea was 10% (95% CI: 0.05-0.14), and the prevalence of anorexia was 17% (95% CI: 0.05-0.28). The prevalence of increased AST, ALT, and TBil were 40% (95% CI: 0.31-0.49), 38% (95% CI: 0.23-0.52), and 18% (95% CI: 0.11-0.26), respectively. The prevalence of digestive system disease and liver disease were 7% (95% CI: 0.00-0.14) and 4% (95% CI: 0.02-0.06), respectively. In non-Wuhan group, 53% of the patients were male. The prevalence of nausea and vomiting was 5% (95% CI: 0.02-0.09), the prevalence of diarrhea was 7% (95% CI: 0.03-0.10), and the prevalence of anorexia was 18% (95% CI: 0.10-0.26). In China group, 55% of the patients were male. The prevalence of nausea and vomiting was 7% (95% CI: 0.05-0.09), the prevalence of diarrhea was 8% (95% CI: 0.06-0.11). The prevalence of increased AST and digestive system disease were 26% (95% CI: 0.18-0.34) and 6% (95% CI: 0.02-0.09), respectively. In non-China group, 47% of the patients were male. The prevalence of nausea and vomiting was 3% (95% CI: −0.01 to 0.07), the prevalence of diarrhea was 13% (95% CI: 0.05-0.21) (Fig. S9 , Supplemental Digital Content 9, http://links.lww.com/JCG/A630). The prevalence of increased AST and digestive system disease were 3% (95% CI: −0.01 to 0.07) and 4% (95% CI: 0.00-0.09).

Only 8 studies were included, the prevalence of nausea and vomiting, diarrhea, abdominal pain, anorexia, increased AST, increased ALT, and liver disease were analyzed. There was no significant difference between general/non-ICU group and severe/ICU group for the prevalence of nausea and vomiting (OR 

In the last 2 decades, the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) had a great effect on global health, the emergence of 2019-nCoV marked the third introduction of a highly morbific coronavirus which could cause epidemics with variable severity of respiratory and extra-respiratory symptoms into the human population. 37 2019-nCoV is the seventh member of the human-infecting coronaviruses family which had 88% identity with 2 bat-derived SARS-like coronaviruses, bat-SL-CoVZC45, and bat-SL-CoVZXC21, and was 79% related to SARS-associated coronavirus (SARS-CoV), 50% related to MERS-associated coronavirus (MERS-CoV), respectively. 38, 39 The main mode of COVID-19 transmission is via droplets and contact, positive reversetranscription polymerase chain reaction (RT-PCR) test for viral RNA from oropharyngeal or nasopharyngeal swabs can help doctors make a quick diagnosis. Notably, laboratories in China declared that they isolated 2019-CoV from stool specimens of patients with COVID-19. 40 A study of 18 patients in Singapore shown that 2019-nCoV was detectable in the stools in 50% of the patients. 41 The first confirmed case in the United State had a history of nausea and vomiting for 2 days followed by diarrhea and abdominal discomfort. 42 Patients could have negative PCR test in oropharyngeal swabs together with positive results in stools. The existence duration of viral RNA in patients' stool specimens is longer than in oropharyngeal swabs, which was essential during convalescence. 43 Besides, angiotensin converting enzyme II (ACE2) which was the cell entry receptor of SARS-CoV has also been confirmed as the cell entry receptor of 2019-nCoV, which could influence the expression of neutral amino acid transporters in gut, change the composition of the gut microbiota, and cause diarrhea and intestinal inflammation. 44, 45 All the information revealed that COVID-19 could influence GI manifestations, and fecal-oral might contribute to the transmission of COVID-19.

Common GI symptoms include nausea, vomiting, diarrhea, abdominal pain, and anorexia. The study of Guan et al 8 showed that 5% of the patients had nausea and vomiting and 3.8% of the patients had diarrhea. The study of Zhang et al 31 showed that 12.2% of the patients had anorexia, 5.8% of the patients had abdominal pain, and 5% of the patients had belching. However, the study of Wang et al 9 showed that 10.1% of the patients had nausea and diarrhea, 39.9% of the patients had anorexia. In this meta-analysis, 7% of the patients had nausea and vomiting, 8% of the patients had diarrhea, 3% of the patients had abdominal pain, and 17% of the patients had anorexia. After reviewing previous studies, we found that the prevalence of GI symptoms of COVID-19 was lower than that of SARS and MERS. Previous studies showed that 40% to 70% of the patients had self-limited watery diarrhea, and 20% to 35% of the patients had nausea and vomiting in SARS infection. 46, 47 Besides, at least one-third of the patients got GI symptoms in MERS infection. 48 Just as the description in above paragraph, ACE2 was identified as cell receptor of 2019-nCoV. Previous study showed that abundant presentation of ACE2 was discovered in esophagus keratinocytes, stomach epithelial cells, intestinal epithelial cells, and colon colonocytes. ACE2 might provide possible routes of entry for 2019-nCoV and played an important role in the GI infection of COVID-19. 49, 50 In order to treat the disease, multiple types of antiviral agents and antibiotic agents were used. Pharmacy expert consensus in China indicated that lopinavir and ritonavir could cause nausea, diarrhea, and vomiting. 51 A previous study showed that the most common adverse events (AEs) of combination therapy of oseltamivir, amantadine, and ribavirin for the treatment of influenza were nausea, diarrhea, and vomiting. 52 The use of antibiotic agents could change the composition and metabolic function of the intestinal microflora, which was essential to the immunity and metabolism. Antibiotic agents might cause dysbacteriosis and contributed to antibioticassociated diarrhea (AAD). 53, 54 The clinical manifestations of AAD varied from mild to severe, severe AAD could have nausea, fever, abdominal pain, and severe watery diarrhea, some patients could have megacolon, even death. Common opportunistic pathogen of severe AAD was Clostridium difficile, a meta-analysis revealed that the most commonly used antibiotic agents were clindamycin, fluoroquinolones, and cephalosporins in clinical practice, and the frequency of clostridium difficile among AAD was 20.2%. 55 Therefore, it is necessary to avoid blindly using medicine, especially the abuse of combination therapy of antiviral agents or antibiotics. A meta-analysis shown that probiotics could reduce risk of AAD in adults, however, the effect in elderly population was not significant. 56 It reminded us that probiotics could be used to relieve GI symptoms.

A considerable number of patients could have abnormal liver function, primarily presented as increased AST, ALT, and TBil. Besides, some patients with normal liver function at baseline could have liver insufficiency during the disease process. In the study of Guan et al, 8 the prevalence of increased AST, ALT, TBil were 22%, 21.3%, and 10.5%, respectively. In the study of Chen et al, 7 1 patient had severe liver function damage with extremely increased ALT (7590 U/L) and AST (1445 U/L). Besides, the study of Zhao et al 33 reported 44.44% of the patients had increased γ-glutamyl, and compared with other types of pneumonia, COVID-19 could cause liver dysfunction more frequently. The study of Liu et al 20 indicated that 17% of the patients, who did not have liver damage at baseline, got liver dysfunction during the process of disease. In this meta-analysis, 24% of the patients had increased AST, 25% of the patients had increased ALT, and 13% of the patients had increased TBil. Reviewing previous studies of SARS and MERS, we found that up to 60% patients could have abnormal liver function in SARS, large numbers of virus particles was found in liver, the liver function impairment was associated with the direct attack of coronavirus or the immune response of viral infection in SARS. 57, 58 The study of Assiri et al 59 shown that 15% of the patients had increased AST and 11% of the patients had increased ALT in MERS. MERS-CoV could bind with host cell dipeptidyl peptidase 4 (DPP4) receptor to enter host cells, and DPP4 was widely expressed on the tissues of liver, which might explain the liver impairment by MERS-CoV. 60, 61 In COVID-19, the liver damage might be associated with several factors. The previous studies shown that ACE2 could express in liver cells and biliary epithelial cells, the level of expression in biliary epithelial cells was similar to that in alveolar type 2 cells in lung, and higher than that in liver cells, which might explain the liver damage in COVID-19. 50, 62 Besides, pharmacy expert consensus in China indicated that lopinavir and ribavirin should been used with caution with the AEs of liver damage. 51 There was a case report of liver dysfunction and alimentary tract hemorrhage caused by oseltamivir in a child, although the AEs of the drug were mostly mild. 63 Therefore, it is essential to monitor the liver function and avoid intensive use of drugs which could cause liver damage, especially in severe patients. Protecting liver therapy could be applied if necessary.

Some patients had digestive system disease and liver disease at the baseline. The study of Chen et al 7 showed that 11% of the patients had digestive system disease. The study of Zhang et al 31 showed that 5.7% of the patients had fatty liver and abnormal liver function, 5% of the patients had chronic gastritis and gastric ulcer, 4.3% patients had cholelithiasis, and 6.4% of the patients received cholecystectomy at the baseline. Compared with other types of viral pneumonia, patients infected by COVID-19 had similar prevalence for liver disease in the study of Bai et al. 11 In this meta-analysis, 5% of the patients had digestive system disease and 3% of the patients had liver disease. A metaanalysis revealed that the pooled mean prevalence of fatty liver disease was 16.73% in China. 64 The prevalence of gastro-oesophageal reflux symptoms was 2.5% in China. 65 The prevalence of gallstone diseases ranged from 4% to 73% around the world. 66 Although we did not acquire all the epidemiological data of digestive system disease and liver disease, it seemed that we could not say people with digestive system disease and liver disease were more likely to have COVID-19.

Compared with non-Wuhan group, the prevalence of nausea and vomiting, diarrhea, abnormal liver function, and digestive system disease was higher in Wuhan group. In Wuhan region, severe patients were admitted to designated hospitals in concentrated way, such as Jinyintan Hospital and Zhongnan Hospital, and the studies included in Wuhan group were mostly from these designated hospitals. The proportion of severe patients in these hospitals might be higher than hospitals in other provinces whose patients were more sporadic. The study of Huang et al 6 which included patients infected early in the COVID-19 outbreak showed that the mortality rate of COVID-19 was 15%. However, in the study of Guan et al 8 which included 1099 cases from 552 hospitals in 30 provinces, autonomous regions in China, the mortality rate is 1.4%. The variation might because of the emergence of more mild-moderate patients.

Compared with general/non-ICU group, the patients in severe/ICU group were more likely to have diarrhea, anorexia, abdominal pain, increased AST, and increased ALT in this meta-analysis. However, there were no significant differences between severe/ICU group and general/non-ICU group for the prevalence of nausea and vomiting and liver disease. The study of Wang and colleagues reported 5% of the patients had vomiting, 14% of the patients had diarrhea or nausea, and there was no significant difference between ICU patients and non-ICU patients. However, patients in ICU were more likely to have abdominal pain, anorexia, and abnormal liver function. 9 In the study of Zhang et al, 31 there was no difference for the prevalence of underlying digestive system disease between severe patients and nonsevere patients. Study of Yang et al 29 showed 29% of the ICU patients had liver dysfunction. The patients with hepatic insufficiency usually had multiple complications such as acute respiratory distress syndrome, respiratory failure, and renal insufficiency, therefore, the liver damage might be the reflection of disease severity and be induced by cytokine release syndrome (CRS). CRS was a systemic inflammatory response caused by a variety of factors such as infection and drugs which could lead to multiorgan system failure, hepatomegaly, hypofibrinogeniemia, liver failure, and abnormal liver enzymes were common in CRS. 67 Besides, the severe patients usually received combination therapy of antivirals agents and antibiotics which could increase the burden of liver.

There were limitations in this meta-analysis. First, classification of digestive system disease and liver disease was unclear in most studies. Second, few studies have performed colonoscopy to observe colon directly, or biopsy of liver and colon to identified the pathologic features. Third, quite a part of included studies had small samples. Most studies were published in China, studies from other countries outside China were needed for further analysis. Besides, the heterogeneity between several studies were high because of varies sample size and different severity among the cases.

Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

Available at: www.who.int/emergencies/diseases/ novel-coronavirus-2019/technical-guidance/naming-the-coronavirusdisease-(covid-2019)-and-the-virus-that-causes-it

Available at: www.who.int/dg/ speeches/detail/who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid

Available at: www.who.int/ dg/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

China medical treatment expert group for C. Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study

Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan

CT imaging features of 2019 novel coronavirus (2019-nCoV)

Eleven faces of coronavirus disease 2019

68 consecutive patients assessed for COVID-19 infection; experience from a UK regional infectious disease unit

Analysis of epidemiological and clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing

A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias

Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) Pneumonia: A Multicenter Study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effect of gastrointestinal symptoms on patients infected with COVID-19

SARS and MERS: recent insights into emerging coronaviruses

A novel coronavirus from patients with pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission

Singapore novel coronavirus outbreak research T. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

First case of 2019 novel coronavirus in the United States

Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients

A pneumonia outbreak associated with a new coronavirus of probable bat origin

ACE2 -from the renin-angiotensin system to gut microbiota and malnutrition

Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection

Severe acute respiratory syndrome: historical, epidemiologic, and clinical Features

State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Novel coronavirus infection: guidance and prevention in hospital pharmacy expert consensus on control strategy (First Edition)

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

Impact of antibiotics on necrotizing enterocolitis and antibiotic-associated diarrhea

Antibiotics in early life: dysbiosis and the damage done

Clostridioides (Clostridium) difficile infection in hospitalized patients with antibiotic-associated diarrhea: a systematic review and metaanalysis

Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly ( > 65 years): a meta-analysis

SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

The multifunctional or moonlighting protein CD26/DPPIV

Middle East respiratory syndrome

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv

Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: a case report

Prevalence of fatty liver disease and the economy in China: a systematic review

Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a metaanalysis

Helicobacter pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: a systematic review and meta-analysis

Cytokine release syndrome